Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Spinal cord injury (SCI) is associated with severe neuropathic pain that is often refractory
to all pharmacological intervention. Preliminary data suggest brivarecetum is a
mechanism-based pharmacological intervention for neuropathic pain in SCI. This randomized,
placebo-controlled pilot clinical trial will assess feasibility of a 3-month treatment course
with brivarecetum.